Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 6/20 | 0.65 |
| ▸ | RARB | P10826 | 6/20 | 0.65 |
| ▸ | RARG | P13631 | 6/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | RXRA | P19793 | 7/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.53 |
| ▸ | RXRB | P28702 | 4/20 | 0.53 |
| ▸ | RXRG | P48443 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | RORC | P51449 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | HTR2B | P41595 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9067692 | 1.00 | RARA (0.65) | RARARARBRARGCYP1A2ALDH1A1 | |
| SCHEMBL10990211 | 1.00 | RARA (0.65) | RARARARBRARGCYP1A2ALDH1A1 | |
| SCHEMBL10993621 | 0.90 | RARA (0.56) | RARARARBRARGCYP1A2ALDH1A1 | |
| SCHEMBL10993619 | 0.90 | RARA (0.56) | RARARARBRARGCYP1A2ALDH1A1 | |
| SCHEMBL10993615 | 0.90 | RARA (0.56) | RARARARBRARGCYP1A2ALDH1A1 | |
| SCHEMBL10993552 | 0.90 | RARA (0.58) | RARARARBRARGCYP1A2ALDH1A1 | |
| SCHEMBL10993555 | 0.90 | RARA (0.58) | RARARARBRARGCYP1A2ALDH1A1 | |
| SCHEMBL10993557 | 0.90 | RARA (0.58) | RARARARBRARGCYP1A2ALDH1A1 | |
| SCHEMBL10987198 | 0.86 | RARA (0.54) | RARARARBRARGCYP1A2ALDH1A1 | |
| SCHEMBL10991291 | 0.86 | RARA (0.54) | RARARARBRARGCYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| US-5587367-A | SYNERGISTIC EFFECT IN TREATING SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-12-24 | — | — | US | claimed |
| EP-0465343-B1 | Pharmaceutical or cosmetical composition comprising a retinoid and a sterol in association | CIRD GALDERMA (FR) | 1994-06-15 | — | — | EP | claimed |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | disclosed |
| US-5587367-A | SYNERGISTIC EFFECT IN TREATING SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-12-24 | — | — | US | disclosed |
| US-5556844-A | SYNERGISTIC, SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-09-17 | — | — | US | disclosed |
| US-4518609-A | ANTITUMOR, SKIN DISORDERS | SRI INTERNATIONAL (US) | 1985-05-21 | — | — | US | disclosed |
| US-4518609-A | ANTITUMOR, SKIN DISORDERS | SRI INTERNATIONAL (US) | 1985-05-21 | — | — | US | disclosed |
| US-4456618-A | ANTITUMOR AGENTS, TREATMENT OF SKIN DISORDERS | SRI INTERNATIONAL (US) | 1984-06-26 | — | — | US | disclosed |
| US-4456618-A | ANTITUMOR AGENTS, TREATMENT OF SKIN DISORDERS | SRI INTERNATIONAL (US) | 1984-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | RARA 1211/4885RARB 987/4885RARG 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.